

1 **ARTICLE TITLE**

2 Pharmacogenomics implementation training improve self-efficacy and competency to drive adoption
3 in clinical practice

4
5 **AUTHOR NAMES**

6 Fadhli Adesta^{1†}, Caroline Mahendra^{1†}, Kathleen Irena Junusmin¹, Arya Melissa Selva Rajah¹, Sharon
7 Goh¹, Levana Sani¹, Alexandre Chan², Astrid Irwanto^{1,3*}

8
9 **AUTHOR AFFILIATIONS**

10 ¹Nalagenetics Pte Ltd, Singapore

11 ²Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences,
12 University of California, Irvine

13 ³Department of Pharmacy, Faculty of Science, National University of Singapore

14 [†]These authors contributed equally to this work.

15 ^{*} Author for correspondence: astrid@nalagenetics.com

16

17 **ABSTRACT**

18 **Background:** Administration of pharmacogenomics (PGx) testing in clinical practice has been
19 suboptimal, presumably due to lack of PGx education. Here, we aim to evaluate the standpoint of
20 PGx testing among a diverse group of healthcare professionals (HCPs) through conducting surveys
21 before and after training. **Materials & Methods:** Training modules were designed to cover 3 key
22 learning objectives and deployed in 5 sections. A pre- and post-training survey questionnaire was
23 used to evaluate participants self-assessments on employing PGx in clinical practice. **Results &**
24 **Conclusion:** Out of all enrollments, 102 survey responses were collected. Overall, respondents agree
25 on the benefits of PGx testing, but have inadequate self-efficacy and competency in utilizing PGx
26 data. Our results show that training significantly improve these, and even leading to greater
27 anticipation of PGx adoption.

28

29 **KEYWORDS:** Healthcare professionals, education, implementation training, pharmacogenomics,
30 programme evaluation

31

32 **INTRODUCTION**

33 Pharmacogenomics (PGx) focuses on the influence of genetic variations on drug response [1]. PGx is
34 progressing from identifying drug-gene pairs to assimilating into clinical practice [2]. A recent study
35 conducted in Singapore observed that 30% of adverse drug reactions (ADRs) were caused by at least
36 one drug with a PGx clinical annotation, suggesting the potential to prevent ADR occurrence via PGx
37 testing [3]. Despite PGx testing demonstrating its potential to enhance medication safety and

38 efficacy [4], its utility in clinical practice has been suboptimal [5], specifically in Asia [6]. The lack of
39 PGx education is an often-cited barrier to the widespread implementation of PGx [7–10].

40 Although PGx didactic teaching is increasing in undergraduate and postgraduate schools of medicine
41 and pharmacy [2,10–15], PGx education is not readily available to practising clinicians [5,10,16].
42 Clinicians may not have sufficient training and educational background to offer patient care
43 incorporating PGx and personalized care overall [5,8]. Consequently, their poor perceived ability to
44 clinically integrate PGx has been widely reported [5,9,10,16,17]. In particular, a survey on
45 Singaporean clinicians practising in psychiatry observed that only 46.4% of respondents felt
46 competent to order PGx tests [5]. In this regard, PGx education may help to bridge the knowledge
47 translation gap of PGx use among clinicians [16].

48 PGx educational courses may be the key to encouraging greater assimilation of PGx into routine
49 practice, having proven to improve attitudes [7] and increase the adoption of testing [18]. A study
50 conducted on physicians observed that a 45-minute PGx presentation can improve their attitudes
51 towards PGx testing [7]. PGx educational courses would have to be constantly updated to ensure
52 sustainable PGx assimilation into routine clinical practice [4,6]. This study is novel because this is the
53 first training material that considers the current level of understanding in Asian healthcare
54 professionals towards pharmacogenomics. It is also novel because of the evaluation of such training
55 material being tested to offline and online healthcare professionals. Therefore, this study aims to
56 evaluate the development and outcomes of a PGx implementation training programme. Participants'
57 perceptions of the clinical relevance and utility of PGx, and their self-efficacy and knowledge to
58 integrate PGx into practice were assessed.

59

60 **MATERIALS AND METHODS**

61 **Study Design and Subjects**

62 This is a mixed method study incorporating two phases: (1) development of training materials and
63 (2) training evaluation measures. In the first phase (development phase), we build the training
64 materials consisting of two versions, TM1 (prototype) and TM2 (finalized). The flow of training
65 delivery is as stated in Fig 1b. Both trainings were conducted by licensed pharmacists who are
66 certified in PGx through American Society of Health-System Pharmacists (ASHP). In the second
67 phase, we assess the designed training materials through pre- and post-surveys after each training.
68 Healthcare professionals (HCPs) were recruited to participate in the focus group discussion (FGD)
69 including medical practitioners (both general practitioners and specialists) as well as pharmacists
70 and students for diversity. Written consent was obtained from FGD participants, highlighting
71 voluntary participation.

72

73 **Phase 1: Development of Training Materials**

74 The content of both training materials focused on the PGx applications. Training outcomes were
75 based on the competency inventory curated by the Pharmacogenetics/Pharmacogenomics Special
76 Interest Group of the American Association of Colleges of Pharmacy [19]. The training objectives
77 were: (1) to understand PGx applications to clinical practice, (2) to engage in patient discussion
78 about PGx testing, and (3) to interpret, evaluate and implement PGx recommendations.

79

80 **Development of Training Material Prototype (TM1)**

81 The “5W1H” approach was adopted for developing the initial training material. Elaborating on the
82 “what, when, why, where, who and how” of PGx systematically introduced fundamental PGx
83 concepts. The training began with “what” PGx is, defining fundamental terminology and key genetic
84 concepts. Information on “where” HCPs may gather relevant PGx information and “how” to
85 manoeuvre through PGx resources, such as PharmGKB, CPIC, and DPWG, was shared. A patient case
86 was used to consolidate four concepts: “when” PGx testing can be implemented, “why” PGx is
87 important, “how” HCPs can interpret PGx information, and “who” to apply PGx to in clinical settings.

88

89 **TM1 Evaluation: Focus Group Discussion (FGD)**

90 TM1 was used to conduct a 30-minute duration offline training before the FGD. The main objective
91 for the FGD was to collect feedback on TM1. The FGD spanned over an hour, was audio-recorded
92 and conducted offline. FGD questions were tailored to explore the participants’ views on the
93 fundamentals of PGx, PGx applications and course delivery. Questions were structured in an open-
94 ended format to facilitate rich discussion. The FGD sequence of questions mirrored the sequence of
95 TM1 content. Additionally, the free-flowing nature of the FGD allowed participants to voice
96 suggestions on supplementary aspects of the training. Feedback collected during this FGD was used
97 to revamp TM1 to TM2.

98

99 **TM2 Implementation**

100 TM2 was used to conduct the final PGx implementation training. The final presentation utilizing TM2
101 was 90 minutes long due to changes in content and was done online via a private e-learning
102 platform. This was due to the COVID-19 pandemic where social distancing was enforced. Therefore,
103 online training was the most appropriate alternative. Pre-post surveys were distributed to
104 participants before and after training respectively. The analysis of these surveys contributed to the
105 validation of TM2.

106

107 **Phase 2: Training Evaluation Measures**

108 We administered pre-training and post-training surveys to evaluate the training materials, both TM1
109 and TM2. Pre- and post-training surveys for TM1 were conducted offline while for TM2 were
110 conducted online. FGD participants brought forward insightful comments regarding blockers to
111 clinical pharmacogenomics implementation in the local context. Thus, feedback from the FGD was
112 used to modify the survey questions in TM1 assessment and the modified survey questions were
113 used to assess TM2, assessing the main blockers of clinical PGx implementation. The surveys,
114 gauging mostly parallel measures, were anonymous and unlinked. Written consent was obtained
115 from the participants, highlighting voluntary participation. Survey questions were adapted from
116 various studies analyzing HCPs’ general PGx perceptions [1,5] and HCPs’ attitudes and knowledge of
117 existing PGx pre- and post-education [7,20]. Due to differing training objectives and varying content,
118 specific modifications were made.

119 The survey consisted of five sections. Perceptions and self-efficacy sections consisted of two sub-
120 sections (P1 and P2; SC1 and SC2) each and utilized five-point Likert scales. Knowledge questions
121 required participants to choose the best multiple choice options. Needs assessment and evaluation

122 of training sections were only included in the post-surveys. Rationales for each section are described
123 below.

124

125 **Data Collection**

126 Data collected was used to characterize the participants. To determine whether training could
127 change clinical practice behaviour, the post-training survey also asked about experience with and
128 anticipation of using PGx tests. An open ended section was incorporated in order to solicit feedback
129 on the training course content and delivery to validate TM2 and facilitate future PGx educational
130 programs.

131 Surveys incorporated the following aspects:

132 1. Perceptions

133 To assess training objective (1), we evaluated for a perception change in clinical relevance (P1) and
134 utility (P2) of PGx. Questions asked in this section are related to how useful PGx is towards the
135 subjects' clinical practice, and in what way PGx is useful.

136 2. Self-efficacy

137 Evaluation of how to utilize PGx data in making drug therapy decisions (SE1) and how to engage in
138 patient discussion about PGx (SE2) were necessary to assess training objectives (2) and (3).
139 Questions asked in this section are related to how competent the subjects feel about implementing
140 PGx practice.

141 3. Knowledge

142 Knowledge, comprehension and application questions regarding clinical PGx recommendations were
143 crafted as a patient case scenario to evaluate for training objective (3). Knowledge assessments were
144 adapted from ASHP's pharmacogenomics professional certification course. Questions assessing the
145 knowledge taught in our developed PGx course were designed by licensed pharmacists who had
146 undergone this ASHP's certification course, this section also included a case study example. The
147 aforementioned concepts were adopted from the first three levels of Bloom's taxonomy, i.e.
148 knowledge (remembering), comprehension (understanding), and application (applying).

149

150 **Statistical Analysis**

151 Ordinal data related to participants' perceptions and self-efficacy were summarized using median
152 and interquartile range (IQR). Items assessed on a five-point Likert scale were collapsed and
153 presented as the percentage of agree, disagree and neutral responses. Distribution of responses
154 between the pre- and post-training surveys were compared using Mann-Whitney U test. Knowledge
155 questions were scored as correct or incorrect, with missing items scored as incorrect. The
156 percentage of correct responses overall and for each question on the pre- and post-training surveys
157 were compared using chi-square test. Statistical analyses were conducted using R Version 3.5.2, with
158 $p < 0.05$ considered as statistically significant.

159

160 **RESULTS**

161 **Phase 1: Development of training materials**

162 TM1 was implemented to train medical professionals who will be involved in a clinical study related
163 to PGx implementation. Due to limited time given for offline training, more-detailed materials such
164 as examples of drug-gene interactions were not explained in TM1. To develop TM2, feedback from
165 training participants was collected through an offline focus group discussion (FGD). Feedback
166 showed that the participants felt there were too few examples on common drug-gene interactions
167 and on how PGx can be implemented in clinical settings. From the feedback received, TM2 was
168 developed to have more in-depth materials, specifically for examples of drug-gene interactions
169 commonly found in clinical settings. More details on the science of PGx and drug-gene interactions
170 were also included in TM2. TM2 implementation was done online to have more flexibility in terms of
171 time and place needed to complete the whole material, as well as scalability. (Fig 1)

172

173 **Characteristics of survey respondents from training**

174 Overall, 102 respondents were collected in our study with 68 in TM1 and 34 in TM2. TM1
175 respondents consisted of 93.4% physicians, of which 68.9% mainly practiced in Family Medicine. On
176 the other hand, TM2 consisted of two major groups of respondents, with majority being 61.8%
177 physicians practicing Family Medicine and 33.3% pharmacy students. More than half of the
178 respondents in TM1 (60.3%) and TM2 (70%) are experienced practitioners with more than 5 years of
179 practice. Prior experience in PGx education is lacking across the respondents, only 27.9% in TM1 and
180 32.4% in TM2. This includes self-learning from independent resources (internet, colleague, journals,
181 drug labels or package inserts), attending a lecture or seminar, and/or enrolling university
182 curriculum. (Table 1)

183

184 **Relevance and utility of pharmacogenomics testing in clinical practice**

185 To understand PGx applications in clinical practice, we evaluated for a perception change in clinical
186 relevance and utility of PGx. This was done by inquiring a set of perception questions pre- and post-
187 training, relative to 5-point Likert-type scale (Fig 2, Table 2). Prior to training, 52.4% in TM1 and
188 62.5% in TM2 participants generally agree or strongly agree on the clinical relevance and utility of
189 PGx testing, indicating favorable perceptions towards PGx. This number increased even more after
190 training to 84.8% in TM1 and 88.1% in TM2. Overall, participants' median scoring in perceptions for
191 TM1 improved from 3 to 4 (Mann-Whitney U test, $p < 0.05$), suggesting statistically significant
192 positive perception change from TM1 training. While the corresponding median score for the online
193 training remained at 4 from TM2 (Mann-Whitney U test, $p < 0.05$). Notably, 77% from TM1 and
194 85.7% from TM2 respondents reported greater anticipation of using PGx tests after attending the
195 training.

196

197 **Perceived ability in the implementation of pharmacogenomics in clinical setting**

198 To evaluate the self-competency of respondents on the utilization of PGx data in making clinical
199 decisions, we assess their ability to engage in PGx discussion, and consider PGx recommendations.
200 We inquire on a set of self-efficacy questions on the perceived belief in ability to use PGx
201 information to guide drug therapy decisions and engagement in patient discussion about PGx
202 testing. Pre-training results demonstrate that respondents begin with inadequate self-efficacy in
203 using PGx data to guide medication therapy and engage with patients (Fig 2, Table 2). Upon

204 completion, both training increased their perceived ability in implementing PGx by 51.5% in TM1 and
205 44.6% in TM2. Participants median scoring in the self-efficacy section for both improved significantly
206 from 2 to 4 in TM1, and 3 to 4 in TM2 (Mann-Whitney U test, $p < 0.05$).

207

208 **Knowledge and proficiency in applying pharmacogenomics to practice**

209 Knowledge, comprehension and application questions were crafted as a patient case scenario to test
210 the ability to interpret, evaluate and implement PGx recommendations following training. Questions
211 were categorized under two sets – knowledge on theoretical PGx and practical clinical
212 implementation of PGx. Respondents were quizzed pre- and post-training, and their performance
213 was assessed to evaluate improvements (Fig 2, Table 3). On average, respondents significantly
214 improved their correct response rate for proficiency questions by 15.1% in TM1 and 28.0% in TM2
215 (Chi-square test, $p < 0.05$). Both training have statistically significant improvements in scores for one
216 knowledge level question under theoretical PGx category (Table 3). On the practical implementation
217 of PGx, significant improvements are seen for an application level in TM1 and a comprehension level
218 in TM2 (Table3).

219

220

221 **DISCUSSION**

222 This study evaluated the outcomes of PGx implementation training which was piloted at Continuing
223 Education (CE) seminars and further developed into an online training module. The aim of the
224 training was to educate respondents about the fundamental PGx theoretical concepts and clinical
225 applications. Here, we found that respondents displayed positive perceptions of the clinical
226 relevance and utility of PGx. We also demonstrated that PGx implementation training conducted as
227 a case-based presentation can improve self-efficacy to clinically apply PGx information and to
228 engage in PGx discussions.

229 There have been scarce resources available for doctors to learn pharmacogenomics online. The only
230 accredited online pharmacogenomics certification course is offered by American Society of Health-
231 System Pharmacists (ASHP). However, this course heavily focuses on how to set up a
232 pharmacogenomics practice, i.e. sourcing labs to run samples and obtaining stakeholder approval.
233 Our course aims to equip the enrollee with the most relevant clinical knowledge at the least amount
234 of time, without going into the administrative details.

235 Prior to training, we observed that respondents portrayed positive perceptions of PGx. These results
236 confirm the forward-thinking attitudinal findings gathered from other studies regarding clinicians'
237 belief in the concept of PGx and its potential benefits to improving drug efficacy and safety
238 [5,14,17,21]. Another study also concluded that their hour-long PGx seminar significantly improved
239 the attitudes of twelve physicians [7]. Advancements in PGx will continue and become more
240 important for patient care to improve drug efficacy and safety [4,22]. Furthermore, their perceptions
241 continued to improve significantly post-training, brightening prospects of increased PGx integration
242 into clinical practice.

243 Conversely, pre-training responses demonstrate low self-efficacy amongst participants to integrate
244 PGx into clinical practice. A knowledge translation gap of PGx use might explain their low perceived
245 competency [5]. Despite efforts to increase PGx education in undergraduate and postgraduate
246 healthcare courses [2,11–15,23,24], PGx educational efforts for clinicians are still not readily
247 available [5,10,16]. Consequently, clinicians lack confidence in their knowledge of what tests are
248 available, when and for whom to order, and how to interpret and incorporate PGx information to
249 drug therapy [4,9]. Therefore, there is a need to advocate for PGx education available to HCP's to
250 improve their self-efficacy in practicing PGx.

251 Training significantly improved participants' self-efficacy to integrate PGx into clinical practice. While
252 clinical experience is associated with increased perceived competency [5], clinicians must already be
253 proficient to provide PGx services when the opportunity arises [10,16]. Hence, it is important to
254 improve clinicians' self-efficacy to apply PGx to practice through education. Our finding indicates a
255 continued need to improve PGx learning, to elevate clinicians' perceived ability in using this
256 therapeutic opportunity and encourage their prevalence in healthcare services.

257 There were improvements in knowledge questions when comparing pre- and post-training
258 responses. Post-offline training, marginal improvements in participants' knowledge were similarly
259 observed after a PGx educational program for pharmacists [20]. On the other hand, post-online
260 training significantly improved the correct response rate. Limited knowledge retention may have
261 been the culprit in subpar improvements for the offline training due to the complexity of PGx or the
262 transfer of overwhelming information over a short period [14,20]. Revisions made to TM2 addressed
263 these pitfalls. Online training materials promote active learning [25] where participants can playback
264 content to enhance knowledge retention. Moreover, complex PGx concepts were more thoroughly
265 explained and quizzes helped to reinforce internalization of content. This is supported by our
266 findings that all participants agreed that the quizzes helped in understanding PGx concepts.
267 Additionally, the online training results reflect a more holistic improvement as the questions were
268 formatted as a case scenario. This has been shown to be more effective for enhancing learning [25].

269 Similar to other studies [5,16,20], respondents express desire to learn more about PGx. Our study
270 demonstrated 77% to 85.7% of respondents also anticipated using PGx tests after training. This
271 highlights the need to develop effective PGx education for HCPs. We recommend introducing
272 structured educational programs for HCPs to learn about PGx. Participants expressed eagerness to
273 learn more about basic concepts of PGx and its application during the trainings. This highlights the
274 need to develop sustainable education for HCPs. Furthermore, we suggest exploring hands-on
275 development of PGx- focused clinical skills as it is vital to the effective adoption of PGx [5,8,14,20].
276 Hence, we recommend integrating point-of-care PGx information into electronic health records
277 [5,26], and making PGx test kits readily available [5].

278 Most of the training materials that are available were developed in a top-down approach, without
279 considering the audience's level of knowledge. This study's focus group discussion discovered that
280 explaining pharmacogenetics concepts using case studies increases efficacy. Moreover, the delivery
281 of training materials offline and online are increasingly important during the pandemic. This study
282 shows that the combination of content, length, design, and platform to conduct training does not
283 interfere with the efficacy of an offline training program. The study also highlights the importance of
284 basic pharmacogenomics training for any healthcare professional interested in implementing it in

285 their practice. Understanding the limitations of time and resources in new markets such as Asia,
286 these training can be offered by teaching hospitals or commercial entities.

287 Our study has several possible limitations. In both training modules, the pre- and post- training
288 survey responses were unlinked. Consequently, we could not analyze changes to individual
289 responses and could only report aggregate data. Our study population were non-randomized and
290 formed a convenient sample, which may imply selection bias for only respondents with PGx
291 interests. While TM1 offline training involved mainly physicians, with limited participation from four
292 pharmacists, TM2 online training had a lower response rate. This may limit the generalizability of our
293 results to the broader population of clinicians. Results from pre- and post-surveys between TM1 and
294 TM2 could also have been impacted by the mode of delivery (offline vs online). Finally, actual
295 implementation of testing and the long-term effects of training were not evaluated. This is because
296 our study was intended to provide baseline and initial assessments of the outcomes of PGx
297 implementation training for clinicians. Therefore, we suggest conducting future studies to follow
298 HCP's over a prolonged period to evaluate the effectiveness of regular PGx educational programs
299 and actual clinical update of PGx integration. A follow-up study is currently underway with our
300 webinar respondents to assess the sustainability of the training's impacts during the clinical
301 implementation of PGx in their practice.

302

303 **CONCLUSION**

304 Overall, respondents have favorable perceptions towards PGx testing, but lack self-efficacy and
305 competency in PGx data utilization. Training has been proven to significantly improve self-efficacy
306 and competency, and lead to greater anticipation of PGx adoption in clinical practice. Online training
307 delivery mode is evidently preferable for further improvements. With its flexibility and scalability, it
308 can be expanded as continuous education over a prolonged period to evaluate the effectiveness of
309 PGx education and integration into clinical practice.

310

311 **FUTURE PERSPECTIVE**

312 Online training delivery mode is evidently preferable for further improvements. With its ability to be
313 flexible and scalable, it can be expanded as continuous education over a prolonged period to
314 evaluate the effectiveness of PGx education and integration into clinical practice.

315

316 **EXECUTIVE SUMMARY**

317 **Background**

- 318 • PGx testing has demonstrated potential to enhance prevention of ADR occurrence in
319 patients with distinguishable genetic variations.
- 320 • However, due to lack of PGx education among HCPs, testing is not administered regularly in
321 clinical practice.
- 322 • PGx education has only seen increase in medical schools, but not in practicing clinicians.

323 **Methods**

- 324 • Training materials were developed to cover theoretical concepts and clinical applications of
325 PGx as implementation training.
326 • PGx implementation training was conducted across diverse group of HCPs including
327 clinicians, pharmacists and students from both fields.
328 • Evaluate changes in thoughts and opinions of respondents pre- and post- training.

329 **Results**

- 330 • Pre- training responses demonstrate respondents already have positive perception of the
331 utility of PGx testing.
332 • Respondents have statistically significant increase in self-assessed efficacy and PGx
333 knowledge upon completion of training.

334 **Conclusion**

- 335 • PGx education improve HCPs self-assessment and encourage adoption of PGx diagnostics to
336 support clinical decisions.
337 • Online training delivery mode is preferred for their flexibility and scalability as continuous
338 education.

339

340 **AUTHOR CONTRIBUTIONS**

341 F.A. and A.I. conceived the study. S.G. and A.M.S.R. designed survey and developed training material
342 with guidance from F.A., L.S., A.C. and A.I. F.A., A.C. and A.I. conducted the trainings. C.M. analysed
343 data collected. C.M. and K.I.J wrote the manuscript with input from all authors

344

345 **ACKNOWLEDGEMENTS**

346 We thank the participants for their time in attending the training courses, focus group discussions
347 and filling our survey. We thank S. Chandrasekaran and M. Tan for assistance in developing the
348 training materials.

349

350 **FINANCIAL DISCLOSURE**

351 F.A., C.M., K.I.J., L.S. and A.I. are employees of Nalagenetics Pte Ltd. A.I. and L.S. has financial
352 holdings in Nalagenetics Pte Ltd. Resources for conducting training and surveys were sponsored by
353 Nalagenetics Pte Ltd. None of the respondents received incentive except for FGD participants who
354 received a small compensation for their transport and time.

355

356 **ETHICAL DISCLOSURE**

357 This study was approved by the institutional review board (IRB No. 038/KEPK/III/2018 for Indonesia;
358 2017/007 for Singapore). Written consent was obtained from FGD participants, highlighting
359 voluntary participation.

360

361 **DATA SHARING STATEMENT**

362 **Will individual participant data be available (including data dictionaries)?**

363 Yes

364 **What data in particular will be shared?**

365 Individual participant data that underlie the results reported in this article, after deidentification
366 (text, tables, figures, and appendices).

367 **What other documents will be available?**

368 None

369 **When will data be available (start and end dates)?**

370 Immediately following publication. No end date.

371 **With whom?**

372 Anyone who wishes to access the data.

373 **For what types of analyses?**

374 Any purpose.

375 **By what mechanism will data be made available?**

376 All data generate or analysed during this study are included in this published article and appendices.

377 Request for additional material should be addressed to A.I.

378 **REFERENCES**

379 Papers of special note have been highlight as: * of interest; ** of considerable interest

- 380 1. Just KS, Steffens M, Swen JJ, Patrinos GP, Guchelaar HJ, Stingl JC. Medical education in
381 pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare
382 professionals within the European pharmacogenomics clinical implementation project
383 Ubiquitous Pharmacogenomics (U-PGx). *Eur. J. Clin. Pharmacol.* [Internet]. 73(10), 1247–1252
384 (2017). Available from: <https://pubmed.ncbi.nlm.nih.gov/28669097/>.
- 385 2. Frick A, Benton CS, Scolaro KL, *et al.* Transitioning pharmacogenomics into the clinical setting:
386 Training future pharmacists. *Front. Pharmacol.* [Internet]. 7(AUG) (2016). Available from:
387 <https://pubmed.ncbi.nlm.nih.gov/27551265/>.
- 388 3. Chan SL, Ang X, Sani LL, *et al.* Prevalence and characteristics of adverse drug reactions at
389 admission to hospital: a prospective observational study. *Br. J. Clin. Pharmacol.* [Internet].
390 82(6), 1636–1646 (2016). Available from: </pmc/articles/PMC5099543/?report=abstract>.
- 391 4. Dunnenberger HM, Crews KR, Hoffman JM, *et al.* Preemptive Clinical Pharmacogenetics
392 Implementation: Current Programs in Five US Medical Centers. *Annu. Rev. Pharmacol.*
393 *Toxicol.* [Internet]. 55(1), 89–106 (2015). Available from:
394 </pmc/articles/PMC4607278/?report=abstract>.
- 395 5. Chan CYW, Chua BY, Subramaniam M, Suen ELK, Lee J. Clinicians’ perceptions of
396 pharmacogenomics use in psychiatry. *Pharmacogenomics* [Internet]. 18(6), 531–538 (2017).
397 Available from: <https://pubmed.ncbi.nlm.nih.gov/28290747/>.
- 398 * Web-based survey conducted to evaluate specific themes on pharmacogenomics including
399 self-assessed competency, perceived usefulness, risks and preferred mode of education.
400 Majority of clinicians acknowledge the potential of pharmacogenomic testing in psychiatric
401 clinical practice.
- 402 6. Lee Y-F, Ching R, Kwok C, *et al.* The Pharmacogenomic Era in Asia: Potential Roles and
403 Challenges for Asian Pharmacists. *J Pharmacogenomics Pharmacoproteomics* [Internet]. 8(1),
404 164 (2017). Available from: www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
- 405 7. Luzum JA, Luzum MJ. Physicians’ attitudes toward pharmacogenetic testing before and after
406 pharmacogenetic education. *Per. Med.* [Internet]. 13(2), 119–127 (2016). Available from:
407 <https://pubmed.ncbi.nlm.nih.gov/29749904/>.
- 408 * Brief PGx education conducted across physicians significantly improve their attitude toward
409 PGx testing
- 410 8. Kisor DF, Bright DR, Chen J, Smith TR. Academic and professional pharmacy education: A
411 pharmacogenomics certificate training program [Internet]. *Per. Med.* 12(6), 563–573 (2015).
412 Available from: <https://pubmed.ncbi.nlm.nih.gov/29750615/>.
- 413 9. Mccullough KB, Formea CM, Berg KD, *et al.* Assessment of the pharmacogenomics
414 educational needs of pharmacists. *Am. J. Pharm. Educ.* [Internet]. 75(3) (2011). Available
415 from: </pmc/articles/PMC3109805/?report=abstract>.
- 416 10. Kisor DF, Farrell CL. Expanding Pharmacist and Student Pharmacist Access to
417 Genetics/Genomics/Pharmacogenomics Competency Education. *J. Med. Educ. Curric. Dev.*
418 [Internet]. 6, 238212051983432 (2019). Available from:
419 </pmc/articles/PMC6415470/?report=abstract>.

- 420 ** PGx certificate training program focused on groups of pharmacists, pharmacy educators and
421 pharmacy students.
- 422 11. Remsberg CM, Bray BS, Wright SK, *et al.* Design, implementation, and assessment approaches
423 within a pharmacogenomics course. *Am. J. Pharm. Educ.* [Internet]. 81(1) (2017). Available
424 from: <https://pubmed.ncbi.nlm.nih.gov/28289301/>.
- 425 12. Marcinak R, Paris M, Kinney SRM. Pharmacogenomics Education Improves Pharmacy Student
426 Perceptions of Their Abilities and Roles in Its Use. *Am. J. Pharm. Educ.* [Internet]. 82(9), 6424
427 (2018). Available from: </pmc/articles/PMC6291667/?report=abstract>.
- 428 13. Frick A, Benton C, Suzuki O, *et al.* Implementing Clinical Pharmacogenomics in the Classroom:
429 Student Pharmacist Impressions of an Educational Intervention Including Personal
430 Genotyping. *Pharmacy* [Internet]. 6(4), 115 (2018). Available from:
431 <https://pubmed.ncbi.nlm.nih.gov/30360487/>.
- 432 14. Adams SM, Anderson KB, Coons JC, *et al.* Advancing pharmacogenomics education in the core
433 pharmd curriculum through student personal genomic testing. *Am. J. Pharm. Educ.* [Internet].
434 80(1) (2016). Available from: </pmc/articles/PMC4776296/?report=abstract>.
- 435 ** Personal genomic testing (PGT) offered in a course of pharmd students to incorporate course
436 materials and exercises using individual-level and population-level genetic data.
437 Implementation of PGT in the curriculum enhanced student learning of pharmacogenomics.
- 438 15. Lee KC, Hudmon KS, Ma JD, Kuo GM. Evaluation of a shared pharmacogenomics curriculum
439 for pharmacy students. *Pharmacogenomics* [Internet]. 16(4), 315–322 (2015). Available from:
440 <https://pubmed.ncbi.nlm.nih.gov/25823780/>.
- 441 16. Kuo GM, Lee KC, Ma JD. Implementation and outcomes of a live continuing education
442 program on pharmacogenomics. *Pharmacogenomics* [Internet]. 14(8), 885–895 (2013).
443 Available from: <https://pubmed.ncbi.nlm.nih.gov/23746183/>.
- 444 17. Stanek EJ, Sanders CL, Taber KAJ, *et al.* Adoption of pharmacogenomic testing by US
445 physicians: Results of a nationwide survey. *Clin. Pharmacol. Ther.* [Internet]. 91(3), 450–458
446 (2012). Available from: <https://pubmed.ncbi.nlm.nih.gov/22278335/>.
- 447 18. Owusu-Obeng A, Weitzel KW, Hatton RC, *et al.* Emerging roles for pharmacists in clinical
448 implementation of pharmacogenomics. *Pharmacotherapy* [Internet]. 34(10), 1102–1112
449 (2014). Available from: </pmc/articles/PMC4188772/?report=abstract>.
- 450 19. Roederer MW, Kuo GM, Kisor DF, *et al.* Pharmacogenomics competencies in pharmacy
451 practice: A blueprint for change [Internet]. *J. Am. Pharm. Assoc.* 57(1), 120–125 (2017).
452 Available from: <https://pubmed.ncbi.nlm.nih.gov/27816542/>.
- 453 20. Formea CM, Nicholson WT, McCullough KB, *et al.* Development and evaluation of a
454 pharmacogenomics educational program for pharmacists. *Am. J. Pharm. Educ.* [Internet].
455 77(1) (2013). Available from: </pmc/articles/PMC3578323/?report=abstract>.
- 456 * PGx education course was conducted amongst pharmacists with accompanying test to
457 evaluate knowledge before and after participation. Results demonstrate knowledge retention
458 is a barrier that requires large effort to increase knowledge and comfort level.
- 459 21. Kudzi W, Addy BS, Dzudzor B. Knowledge of Pharmacogenetics among Healthcare
460 Professionals and Faculty Members of Health Training Institutions in Ghana. *Ghana Med. J.*
461 [Internet]. 49(1), 50–56 (2015). Available from: </pmc/articles/PMC4549817/?report=abstract>.

- 462 22. Moen M, Lamba J. Assessment of healthcare students views on pharmacogenomics at the
463 University of Minnesota. *Pharmacogenomics* [Internet]. 13(13), 1537–1545 (2012). Available
464 from: [/pmc/articles/PMC3562085/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/26907849/).
- 465 23. O'Brien TJ, Lelacheur S, Ward C, Lee NH, Callier S, Harralson AF. Impact of a personal CYP2D6
466 testing workshop on physician assistant student attitudes toward pharmacogenetics.
467 *Pharmacogenomics* [Internet]. 17(4), 341–352 (2016). Available from:
468 <https://pubmed.ncbi.nlm.nih.gov/26907849/>.
- 469 24. Patrinos GP, Katsila T. Pharmacogenomics education and research at the Department of
470 Pharmacy, University of Patras, Greece. *Pharmacogenomics* [Internet]. 17(17), 1865–1872
471 (2016). Available from: <https://pubmed.ncbi.nlm.nih.gov/27790924/>.
- 472 25. Gleason BL, Peeters MJ, Resman-Targoff BH, *et al*. An active-learning strategies primer for
473 achieving ability-based educational outcomes. [Internet]. *Am. J. Pharm. Educ.* 75(9), 186
474 (2011). Available from: [/pmc/articles/PMC3230347/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/26907849/).
- 475 ** Active learning involves actively engaging in the classroom teaching-learning process. This
476 review highlights evidences that support the use of active-learning strategies in pharmacy
477 education and provide strategies on their implementation.
- 478 26. Vitek CRR, Nicholson WT, Schultz C, Caraballo PJ. Evaluation of the use of clinical decision
479 support and online resources for pharmacogenomics education. *Pharmacogenomics*
480 [Internet]. 16(14), 1595–1603 (2015). Available from:
481 <https://pubmed.ncbi.nlm.nih.gov/26419532/>.
- 482

483 TABLES

484 **Table 1.** Participant Characteristics in Offline and Online Training.

| Characteristics | Offline; TM1 | | | | Online; TM2 | | | |
|--|--------------|---------|--------------|---------|-------------|---------|--------------|---------|
| | Pre, n = 68 | | Post, n = 61 | | Pre, n = 34 | | Post, n = 21 | |
| | n | % | n | % | n | % | n | % |
| Age (mean and range) | 42.1 | (24-73) | 43.1 | (24-73) | 30.41 | (23-50) | 29.69 | (23-46) |
| Gender | | | | | | | | |
| Male | 33 | 48.5 | 32 | 52.5 | 19 | 55.9 | 10 | 47.6 |
| Female | 28 | 41.2 | 21 | 34.4 | 15 | 44.1 | 11 | 52.4 |
| Position | | | | | | | | |
| Doctor | 63 | 92.6 | 57 | 93.4 | 0 | 0.0 | 0 | 0.0 |
| Pharmacist | 4 | 5.9 | 3 | 4.9 | 1 | 2.9 | 1 | 4.8 |
| Nurse | 0 | 0.0 | | 0.0 | 2 | 5.9 | 2 | 9.5 |
| Medical Student | 0 | 0.0 | 47 | 77.0 | 3 | 8.8 | 3 | 14.3 |
| Pharmacy Student | 0 | 0.0 | 1 | 1.6 | 7 | 20.6 | 7 | 33.3 |
| Others | 1 | 1.5 | 1 | 1.6 | 0 | 0.0 | 0 | 0.0 |
| Specialty | | | | | | | | |
| Family medicine | 44 | 64.7 | 42 | 68.9 | 21 | 61.8 | 8 | 38.1 |
| Surgery | 1 | 1.5 | 2 | 3.3 | 0 | 0.0 | 0 | 0.0 |
| Emergency Medicine | 1 | 1.5 | 0 | 0.0 | 2 | 5.9 | 2 | 9.5 |
| Others | 8 | 11.9 | 3 | 4.8 | 0 | 0.0 | 0 | 0.0 |
| Not applicable | 1 | 1.5 | 1 | 1.6 | 11 | 32.4 | 11 | 52.4 |
| Practice experience | | | | | | | | |
| 1 to 5 years | 18 | 26.5 | 15 | 24.6 | 10 | 29.4 | 6 | 28.6 |
| 6 to 10 years | 11 | 16.2 | 10 | 16.4 | 4 | 11.8 | 2 | 9.5 |
| 11-20 years | 12 | 17.6 | 10 | 16.4 | 7 | 20.6 | 3 | 14.3 |
| 21-30 years | 11 | 16.2 | 9 | 14.8 | 3 | 8.8 | 0 | 0.0 |
| 31-40 years | 3 | 4.4 | 4 | 6.6 | 0 | 0.0 | 0 | 0.0 |
| 41-50 years | 1 | 1.5 | 1 | 1.6 | 0 | 0.0 | 0 | 0.0 |
| Previous experience with PGx education | 19 | 27.9 | | | 11 | 32.4 | | |

485

486 **Table 2.** Pre- and post-training results related to perceptions and self-efficacy of addressing PGx
 487 testing.

| Survey items | Offline; TM1 | | | | | Online; TM2 | | | | |
|--|---------------------------|------------------|---------------------------|------------------|----------------------|---------------------------|------------------|---------------------------|------------------|----------------------|
| | Pre, n = 68 | | Post, n = 61 | | p-value ^c | Pre, n = 34 | | Post, n = 21 | | p-value ^c |
| | Median Score ^a | IQR ^b | Median Score ^a | IQR ^b | | Median Score ^a | IQR ^b | Median Score ^a | IQR ^b | |
| Perceptions (P1): Relevance of PGx to clinical practice | | | | | | | | | | |
| P1-1 PGx is relevant to my clinical practice / I am keen in adopting PGx into my clinical practice | 3 | 2 | 4 | 0 | < 0.05 | 4 | 1 | 4 | 1 | < 0.05 |
| P1-2 I believe that a patient's genetic profile may influence his/her response to drug therapy. | 4 | 1 | 4 | 1 | < 0.05 | 4 | 0 | 4 | 1 | < 0.05 |
| Perceptions (P2): Clinical utility of PGx | | | | | | | | | | |
| P2-1 In general, the benefits of PGx testing outweigh the risks. | 3 | 1 | 4 | 1 | < 0.05 | 4 | 1 | 4 | 0 | < 0.05 |
| P2-.. PGx testing is useful for... | | | | | | | | | | |
| P2-2 ...identifying suitable medications for treatment. | 4 | 1 | 4 | 1 | < 0.05 | 4 | 1 | 4 | 1 | < 0.05 |
| P2-3 ...guiding dosing of medications. | 3 | 1 | 4 | 1 | < 0.05 | 4 | 1 | 4 | 1 | < 0.05 |
| P2-4 ...reducing adverse drug reactions. | 4 | 1 | 4 | 1 | < 0.05 | 4 | 0 | 5 | 1 | < 0.05 |
| P2-5 ...improving treatment efficacy. | 4 | 1 | 4 | 1 | < 0.05 | 4 | 1 | 5 | 1 | < 0.05 |
| P2-6 ...reducing treatment costs. | 3 | 1 | 4 | 2 | < 0.05 | 3 | 1 | 4 | 1 | 0.1092 |
| Self-efficacy (SE1): Perceived belief in ability to use PGx information to guide drug therapy decisions | | | | | | | | | | |
| SE1-.. I feel competent in ... | | | | | | | | | | |
| SE1-1 ...identifying clinical situations and/or patients in which PGx testing is indicated. | 3 | 1 | 4 | 1 | < 0.05 | 3 | 2 | 4 | 1 | < 0.05 |
| SE1-2 ...interpreting PGx test results. | 2 | 1 | 4 | 1 | < 0.05 | 3 | 1 | 4 | 1 | < 0.05 |
| SE1-3 ...making treatment recommendations based on PGx test results. | 2 | 1 | 4 | 1 | < 0.05 | 3 | 1 | 4 | 1 | < 0.05 |
| SE1-4 I can identify good PGx resources (e.g. guidelines) for use clinically. | 2 | 1 | 4 | 1 | < 0.05 | 3 | 2 | 4 | 1 | < 0.05 |
| Self-efficacy (SE2): Perceived belief in ability to engage in patient discussion about PGx testing | | | | | | | | | | |
| SE2-1 I feel competent in explaining the rationale of PGx testing to patients. | 3 | 1 | 4 | 1 | < 0.05 | 3 | 2 | 4 | 0 | < 0.05 |
| SE2-2 I feel competent in discussing the risks and benefits of PGx testing with patients. | 2 | 1 | 4 | 1 | < 0.05 | 3 | 2 | 4 | 1 | < 0.05 |

488 ^aScore is ranged using five-point Likert scale from (1) strongly disagree to (5) strongly agree.

489 ^bIQR is calculated as the difference in scores falling in the 1st and 3rd quartile.

490 ^cMann-Whitney U test was used to analyse changes in pre- and post- training responses. Significant
 491 p-values (<0.05) are bolded.

492 **Table 3.** Correct responses to questions about knowledge on PGx comparing pre- and post- online
 493 training for TM1 and TM2

| Survey Questions | Correct Answer | Correct Responses | | | | | | | | | |
|---|---|-------------------|-----|------|-----|---------------------|-------------|-----|------|------|---------------------|
| | | Offline; TM1 | | | | | Online; TM2 | | | | |
| | | Pre | | Post | | p-value | Pre | | Post | | p-value |
| | | n | % | n | % | | n | % | n | % | |
| Knowledge (K1): Knowledge on theoretical PGx | | | | | | | | | | | |
| K1-1. What may be the consequence of a PGx polymorphism? (comprehension level) | An individual has a higher risk for toxicity when using prescription drugs. | 40 | 59% | 43 | 65% | 0.4507 ^a | 9 | 43% | 4 | 50% | 1 ^b |
| K1-2. What does a poor metabolizer phenotype indicate? (knowledge level) | Decreased enzyme activity. | 17 | 25% | 18 | 27% | 0.7646 ^a | 13 | 62% | 5 | 63% | 1 ^b |
| K1-3. A patient with CYP2D6 activity score of 1.5 has which CYP2D6 phenotype? (knowledge level) | Normal metabolizer. | 6 | 38% | 10 | 63% | 0.1573 ^a | | | | | |
| K1-4. Which of the following is not correct about pre-emptive and reactive genotyping? (knowledge level) | Reactive genotyping has been shown to be more cost-effective than pre-emptive genotyping. | 14 | 27% | 28 | 56% | < 0.05 ^a | 4 | 19% | 1 | 13% | 1 ^b |
| K1-5. What does an ultra-rapid metabolizer phenotype for CYP2C19 indicate? (knowledge level) | Increased enzyme activity | | | | | | 5 | 38% | 13 | 100% | < 0.05 ^b |
| Knowledge (K2): Practical clinical implementation of PGx | | | | | | | | | | | |
| K2-1. There is a high chance that Ms Lee will develop Stevens Johnsons Syndrome? (comprehension level) | FALSE | | | | | | 8 | 62% | 12 | 92% | 0.1602 ^b |
| K2-2. What is Ms Lee's CYP2D6 enzyme activity score? (comprehension level) | 2 | | | | | | 2 | 15% | 13 | 100% | < 0.05 ^a |
| K2-3. Which of the following would be appropriate regarding Ms Lee's amitriptyline therapy according to CPIC guidelines? (application level) | Consider alternative drug not metabolized by CYP2C19 | | | | | | 1 | 8% | 1 | 8% | 1 ^b |
| K2-4. A woman is diagnosed with breast cancer and, as part of her oncology regimen, she is treated with tamoxifen. She did not have genetic testing performed before initiating treatment. What PGx reason would cause the treating physician to decide to change the drug? (application level) | CYP2D6 poor metabolizer resulting in lack of drug. | 11 | 69% | 10 | 63% | 0.7097 ^a | | | | | |
| K2-5. Which of the following would be appropriate regarding clopidogrel therapy in patients who are CYP2C19 poor metabolizers? (application level) | Consider alternative antiplatelet therapy if no contraindications. | 15 | 29% | 31 | 62% | < 0.05 ^a | | | | | |

494 ^aChi-square test was used to compare the percentage of correct responses between pre- and post-
 495 training surveys. Significant p-values (<0.05) are bolded.

496 ^bFisher's test was used if criteria for Chi-square (expected value size > 5) is not met.

497

498

499

500

501


502

503

504

505

506 FIGURES



507

508

509 **Fig.1 | Development of training materials.** **a**, Questions composed of 5W1H (what, when, why,
 510 where, who, and how) are used to determine the first training materials and objectives. **b**, The first
 511 training material (TM1) was designed based 5W1H questions as seen on Figure 1a and implemented
 512 in an offline training. Focus group discussion (FGD) with the TM1's training participants was held
 513 offline to collect feedback. Feedback from the FGD was used to develop a more comprehensive
 514 training materials (TM2) and implemented as online training. **c**, Details of the learning objectives and
 515 topics covered in TM1 and TM2.

516


517

518

519

520

521



522

523 **Fig.2 | Overall percent of respondents relative to 5-point Likert-type scale labels pre- and post-PGx**
 524 **training conducted a, Offline, TM1; and b, Online, TM2.** Survey domains included Perceptions of the
 525 relevance and clinical utility of PGx, Self-Efficacy through perceived ability to use PGx information in
 526 guiding medical decisions and engage in patient discussions about PGx testing, and Knowledge
 527 questions on the PGx-based case studies. ^aTM1 respondents pre-training, n = 68. ^bTM1 respondents
 528 post-training, n = 61. ^cTM2 respondents pre-training, n = 34. ^dTM2 respondents post-training, n = 21.
 529 *Statistically significant p-values (p < 0.05) were observed in changes from pre- and post- training
 530 responses.

531

532

533

534

535

536

537

538

539 **Appendix 1: Pre-training survey for TM1**

540 **Survey 1: Pre-training pharmacogenomics survey**

541

542 **Introduction**

543 Pharmacogenomics is the study of how genes affect an individual’s response to drugs. This survey
 544 aims to examine clinicians’ knowledge and perceptions of the clinical use of pharmacogenomics
 545 testing. This survey should take approximately 5 minutes to complete; thank you for your time.

546 Please rate the following (circle your answer):

547 **Section 1: Perceptions**

548

549 1. Pharmacogenomics is useful to my current practice.

550

| | | | | |
|-------------------|---|---|----------------|---|
| Strongly Disagree | | | Strongly Agree | |
| 1 | 2 | 3 | 4 | 5 |

551

552 2. I believe that a patient’s genetic profile may influence his/her response to drug therapy.

553

| | | | | |
|-------------------|---|---|----------------|---|
| Strongly Disagree | | | Strongly Agree | |
| 1 | 2 | 3 | 4 | 5 |

554

555 3. In general, the benefits of pharmacogenomics testing outweigh the risks.

556

| | | | | |
|-------------------|---|---|----------------|---|
| Strongly Disagree | | | Strongly Agree | |
| 1 | 2 | 3 | 4 | 5 |

557

558 4. Is pharmacogenomics testing useful for the following?

559

| | Not useful at all | | | Extremely useful | |
|--|-------------------|---|---|------------------|---|
| (a) Identifying suitable medications for treatment | 1 | 2 | 3 | 4 | 5 |
| (b) Guide dosing of medications | 1 | 2 | 3 | 4 | 5 |
| (c) Reducing adverse drug reactions | 1 | 2 | 3 | 4 | 5 |
| (d) Improving treatment efficacy | 1 | 2 | 3 | 4 | 5 |

| | | | | | |
|------------------------------|---|---|---|---|---|
| (e) Reducing treatment costs | 1 | 2 | 3 | 4 | 5 |
|------------------------------|---|---|---|---|---|

560

561 **Section 2: Ability**

562

563 5. Please rank your perceived ability:

564 (a) I feel competent in identifying clinical situations and/or patients in which pharmacogenomics
565 testing is indicated.

566

| | | | | | |
|-------------------|---|---|----------------|---|--|
| Strongly Disagree | | | Strongly Agree | | |
| 1 | 2 | 3 | 4 | 5 | |

567

568 (b) I feel competent in interpreting results of pharmacogenomics tests.

569

| | | | | | |
|-------------------|---|---|----------------|---|--|
| Strongly Disagree | | | Strongly Agree | | |
| 1 | 2 | 3 | 4 | 5 | |

570

571 (c) I feel competent in making treatment recommendations based on results.

572

| | | | | | |
|-------------------|---|---|----------------|---|--|
| Strongly Disagree | | | Strongly Agree | | |
| 1 | 2 | 3 | 4 | 5 | |

573

574 (d) I can identify good pharmacogenomics resources (e.g. guidelines) for use clinically.

575

| | | | | | |
|-------------------|---|---|----------------|---|--|
| Strongly Disagree | | | Strongly Agree | | |
| 1 | 2 | 3 | 4 | 5 | |

576

577 (e) I feel competent in explaining the rationale of pharmacogenomics testing to patients.

578

| | | | | | |
|-------------------|---|---|----------------|---|--|
| Strongly Disagree | | | Strongly Agree | | |
| 1 | 2 | 3 | 4 | 5 | |

579

580 (f) I feel competent in discussing the risks and benefits of pharmacogenomics testing with patients.

581

| | | | | | |
|-------------------|---|---|----------------|---|--|
| Strongly Disagree | | | Strongly Agree | | |
| 1 | 2 | 3 | 4 | 5 | |

582

583 **Section 3: Knowledge**

584

585 6. What may be the consequence of a pharmacogenomics polymorphism?

586

- 587
- An individual cannot metabolize any drugs
 - An individual has a higher risk for toxicity when using prescription drugs
 - A single drug dose is appropriate for a given indication
 - Individualized dose adjustments should be made according to body surface area
- 591

592 7. What does a poor metabolizer phenotype indicate?

593

- 594
- Lower drug safety because of poor metabolism
 - Good drug efficacy because of poor metabolism
 - Decreased enzyme activity
 - Increased enzyme activity
- 598

599 8. Which of the following is **not** correct about pre-emptive and reactive genotyping?

600

- 601
- Reactive genotyping is ordered as a drug therapy is being initiated or contemplated.
 - Pre-emptive genotyping allows pharmacogenomics information to be available to guide prescribing.
 - Reactive genotyping has been shown to be more cost-effective than pre-emptive genotyping.
 - Pre-emptive genotyping usually tests for a panel of genes, whereas reactive genotyping usually tests for one to two genes.
- 607

608 9. Which of the following would be appropriate regarding clopidogrel therapy in patients who are CYP2C19 poor metabolizers?

609

- 610
- Initiate therapy with recommended starting dose
 - Consider a 25% increase of recommended starting dose
 - Consider a 25% decrease of recommended starting dose
 - Consider alternative antiplatelet therapy if no contraindications
- 615

616 10. What sources have you used to learn about pharmacogenomics testing and its applications?

617

618 (please select all that apply)

- 619
- Undergraduate education curriculum
 - Postgraduate education curriculum
 - Internet, website: _____
 - Seminar, seminar name: _____
 - Journal, journal name: _____
 - Drug labels (package inserts)
 - Colleague
 - I have not learnt about pharmacogenomics testing and its applications
 - Other (please specify): _____
- 627

628

629 **Section 4: Demographics**

630

631 11. Year of birth: _____

632

633 12. Gender: Male Female

634

635 13. Position:

636

- 637 • Doctor
- 638 • Pharmacist
- 639 • Nurse
- 640 • Other (please specify): _____

641

642 14. Main practice specialty: _____

643

644 15. Number of years of practice experience: _____

645

646

647 **Appendix 2: Post-training survey for TM1**

648 **Survey 2: Post-training pharmacogenomics survey**

649

650 Please rate the following (circle your answer):

651

652 **Section 1: Perceptions**

653

654 1. Pharmacogenomics is useful to my current practice.

655

| Strongly Disagree | | | Strongly Agree | |
|-------------------|---|---|----------------|---|
| 1 | 2 | 3 | 4 | 5 |

656

657 2. I believe that a patient's genetic profile may influence his/her response to drug therapy.

658

| Strongly Disagree | | | Strongly Agree | |
|-------------------|---|---|----------------|---|
| 1 | 2 | 3 | 4 | 5 |

659

660 3. In general, the benefits of pharmacogenomics testing outweigh the risks.
661

| Strongly Disagree | | | Strongly Agree | |
|-------------------|---|---|----------------|---|
| 1 | 2 | 3 | 4 | 5 |

662

663 4. Is pharmacogenomics testing useful for the following?
664

| | Not useful at all | | | Extremely useful | |
|--|-------------------|---|---|------------------|---|
| (a) Identifying suitable medications for treatment | 1 | 2 | 3 | 4 | 5 |
| (b) Guide dosing of medications | 1 | 2 | 3 | 4 | 5 |
| (c) Reducing adverse drug reactions | 1 | 2 | 3 | 4 | 5 |
| (d) Improving treatment efficacy | 1 | 2 | 3 | 4 | 5 |
| (e) Reducing treatment costs | 1 | 2 | 3 | 4 | 5 |

665

666 Section 2: Ability

667

668 Please rank your perceived ability:

669

670 (a) I feel competent in identifying clinical situations and/or patients in which pharmacogenomics
671 testing is indicated.

672

| Strongly Disagree | | | Strongly Agree | |
|-------------------|---|---|----------------|---|
| 1 | 2 | 3 | 4 | 5 |

673

674 (b) I feel competent in interpreting results of pharmacogenomics tests.

675

| Strongly Disagree | | | Strongly Agree | |
|-------------------|---|---|----------------|---|
| 1 | 2 | 3 | 4 | 5 |

676

677 (c) I feel competent in making treatment recommendations based on results.

678

| Strongly Disagree | | | Strongly Agree | |
|-------------------|--|--|----------------|--|
|-------------------|--|--|----------------|--|

| | | | | |
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|

679

680 (d) I can identify good pharmacogenomics resources (e.g. guidelines) for use clinically.

681

| | | | | |
|-------------------|---|---|----------------|---|
| Strongly Disagree | | | Strongly Agree | |
| 1 | 2 | 3 | 4 | 5 |

682

683 (e) I feel competent in explaining the rationale of pharmacogenomics testing to patients.

684

| | | | | |
|-------------------|---|---|----------------|---|
| Strongly Disagree | | | Strongly Agree | |
| 1 | 2 | 3 | 4 | 5 |

685

686 (f) I feel competent in discussing the risks and benefits of pharmacogenomics testing with patients.

687

| | | | | |
|-------------------|---|---|----------------|---|
| Strongly Disagree | | | Strongly Agree | |
| 1 | 2 | 3 | 4 | 5 |

688

689 Section 3: Knowledge

690

691 5. What may be the consequence of a pharmacogenomics polymorphism?

692

- 693 • An individual cannot metabolize any drugs
- 694 • An individual has a higher risk for toxicity when using prescription drugs
- 695 • A single drug dose is appropriate for a given indication
- 696 • Individualized dose adjustments should be made according to body surface area

697

698 6. What does a poor metabolizer phenotype indicate?

699

- 700 • Lower drug safety because of poor metabolism
- 701 • Good drug efficacy because of poor metabolism
- 702 • Decreased enzyme activity
- 703 • Increased enzyme activity

704

705 7. Which of the following is **not** correct about pre-emptive and reactive genotyping?

706

- 707 • Reactive genotyping is ordered as a drug therapy is being initiated or contemplated.
- 708 • Pre-emptive genotyping allows pharmacogenomics information to be available to guide prescribing.
- 709 • Reactive genotyping has been shown to be more cost-effective than pre-emptive genotyping.

710

711 • Pre-emptive genotyping usually tests for a panel of genes, whereas reactive genotyping
 712 usually tests for one to two genes.
 713

714 8. Which of the following would be appropriate regarding clopidogrel therapy in patients who are
 715 CYP2C19 poor metabolizers?
 716

- 717 • Initiate therapy with recommended starting dose
- 718 • Consider a 25% increase of recommended starting dose
- 719 • Consider a 25% decrease of recommended starting dose
- 720 • Consider alternative antiplatelet therapy if no contraindications

722 **Section 4: Needs assessment**

723

724 9. To better utilize pharmacogenomics information in the management of drug therapy, I would
 725 need... (please select all that apply)
 726

- 727 • Better knowledge on pharmacology
- 728 • Better knowledge on drug metabolism
- 729 • Better knowledge on the basic concepts of pharmacogenomics
- 730 • Stronger evidence that pharmacogenomics improves clinical outcomes
- 731 • Better ability to apply my knowledge
- 732 • Better knowledge of legal regulations
- 733 • Support of my working institution
- 734 • Insurance coverage
- 735 • Expert counsel
- 736 • Other (please specify): _____

737

738 10. What is your preferred format for learning more about pharmacogenomics? (please select all that
 739 apply)
 740

- 741 • Lectures
- 742 • Journal clubs
- 743 • Medical app
- 744 • E-learning
- 745 • Case discussion
- 746 • Other (please specify): _____

747

748 **Section 5: Evaluation of the training**

749

750 11. Please rate the following:
 751

| | Strongly disagree | | | Strongly agree | |
|---|-------------------|---|---|----------------|---|
| | 1 | 2 | 3 | 4 | 5 |
| (a) The topics covered were relevant to me. | | | | | |

| | | | | | |
|---|---|---|---|---|---|
| (b) The content was organized and easy to follow. | 1 | 2 | 3 | 4 | 5 |
| (c) The patient case aided my understanding of the clinical applications of pharmacogenomics. | 1 | 2 | 3 | 4 | 5 |
| (d) The training expanded my knowledge on pharmacogenomics. | 1 | 2 | 3 | 4 | 5 |

752

753 **Section 6: Demographics**

754

755 12. Within the past 6 months, how often have you ordered or recommended a pharmacogenomics
756 test?

757

- 758 • 0
- 759 • 1 time per month
- 760 • 2-5 times per month
- 761 • >5 times per month

762

763 13. Do you anticipate ordering or recommending a pharmacogenomics test for a patient within the
764 next 6 months?

765

- 766 • Yes
- 767 • No

768

769 14. Year of birth: _____

770

771 15. Gender: Male Female

772

773 16. Position:

774

- 775 • Doctor
- 776 • Pharmacist
- 777 • Nurse
- 778 • Other (please specify): _____

779

780 17. Main practice specialty: _____


781

782 18. Number of years of practice experience: _____

783

784 19. Please list any additional comments or feedback here:

785



786

787

788 **Appendix 3: Pre-training survey for TM2**

789 **Nalagenetics Pharmacogenomics Pre-Training Survey**

790 We are Nalagenetics and we are creating a pharmacogenomics (PGx) program to integrate
 791 PGx into clinical practice. Pharmacogenomics is the study of how genes affect an
 792 individual's response to drugs. One of the main benefits of PGx is to prevent and minimize
 793 adverse drug reactions (ADRs). This survey aims to gain feedback on our existing prototype
 794 PGx course. It will take approximately 10 minutes to complete, thank you for your time.

795 *Required

796

797 **Perceptions**

798 1. Are you currently integrating PGx into your clinical practice? *

799 a. Yes

800 b. No

801 2. Please rate the following: * (Mark only one oval per row.)

| | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
|--|-------------------|----------|---------|-------|----------------|
| I am keen in adopting PGx into my clinical practice. | | | | | |
| My patients experience ADRs from their prescribed medications. | | | | | |
| I believe that a patient's genetic profile may influence his/her response to drug therapy. | | | | | |
| In general, the benefits of pharmacogenomics testing outweigh the risks. | | | | | |
| I am keen in adopting PGx into my clinical practice. | | | | | |
| My patients experience ADRs from their prescribed medications. | | | | | |
| I believe that a patient's genetic profile may influence his/her response to drug therapy. | | | | | |
| In general, the benefits of | | | | | |

| | | | | | |
|--|--|--|--|--|--|
| pharmacogenomics testing outweigh the risks. | | | | | |
|--|--|--|--|--|--|

802

803 3. PGx is useful for the following: * (Mark only one oval per row.)

| | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
|--|-------------------|----------|---------|-------|----------------|
| (a) Choosing the best treatment option | | | | | |
| (b) Optimizing drug dosing regimen | | | | | |
| (c) Minimizing ADRs | | | | | |
| (d) Improving treatment efficacy | | | | | |
| (e) Reducing treatment costs | | | | | |

804

805 4. Some of the obstacles involved in implementing PGx into my clinical practice are: * (Mark
806 only one oval per row.)

| | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
|---------------------------------------|-------------------|----------|---------|-------|----------------|
| (a) Cost | | | | | |
| (b) Turn around time | | | | | |
| (c) Lack of clear guidelines/evidence | | | | | |
| (d) Confuse/worry patients | | | | | |
| (e) PGx is not accurate | | | | | |
| (f) PGx is not applicable to me | | | | | |

807

808 **Ability**

809 5. If I were to adopt PGx into my clinical practice, I know how to do the following: * (Mark
810 only one oval per row.)

| | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
|--|-------------------|----------|---------|-------|----------------|
| (a) Identifying clinical situations/patients in which PGx is indicated | | | | | |
| (b) Interpret PGx test results | | | | | |
| (c) Make treatment recommendations based on PGx results | | | | | |
| (d) Identify good PGx resources for clinical use | | | | | |
| (e) Explain the rationale of PGx testing to my patients | | | | | |
| (f) Discuss the risks and benefits of PGx testing | | | | | |

811

812 **Knowledge**

813 6. What may be the consequence of a pharmacogenomics polymorphism? (Mark only one
814 oval.)

- 815 a. An individual cannot metabolize any drugs
- 816 b. An individual has a higher risk for toxicity when using prescription drugs
- 817 c. A single drug dose is appropriate for a given indication
- 818 d. Individualized dose adjustments should be made according to body surface area

820 7. What does a poor metabolizer phenotype indicate? (Mark only one oval.)

- 821 a. Lower drug safety because of poor metabolism
- 822 b. Good drug efficacy because of poor metabolism
- 823 c. Decreased enzyme activity
- 824 d. Increased enzyme activity

826 8. Which of the following is not correct about pre-emptive and reactive genotyping? (Mark
827 only one oval.)

- 828 a. Reactive genotyping is ordered as a drug therapy is being initiated or contemplated.
- 829 b. Pre-emptive genotyping allows pharmacogenomics information to be available to
830 guide prescribing.
- 831 c. Reactive genotyping has been shown to be more cost-effective than pre-emptive
832 genotyping.
- 833 d. Pre-emptive genotyping usually tests for a panel of genes, whereas reactive
834 genotyping usually tests for one to two genes.

836 **Evaluation**

837 9. Please rate the following: * (Mark only one oval per row.)

| | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
|---|-------------------|----------|---------|-------|----------------|
| The topics covered were relevant to me. | | | | | |
| The content was organized and easy to follow. | | | | | |
| The patient case aided my understanding of the clinical applications of pharmacogenomics. | | | | | |
| The training expanded my knowledge on pharmacogenomics. | | | | | |

838

839 **Appendix 4: Post-training survey for TM2**

840 **Nalagenetics Pharmacogenomics Post-Training Survey**

841 We are Nalagenetics and we are creating a pharmacogenomics (PGx) program to integrate
842 PGx into clinical practice. Pharmacogenomics is the study of how genes affect an
843 individual's response to drugs. One of the main benefits of PGx is to prevent and minimize
844 adverse drug reactions (ADRs). This survey aims to gain feedback on our existing prototype
845 PGx course. It will take approximately 10 minutes to complete, thank you for your time.

846 *Required

847

848 1. Age Group: * Mark only one oval.

849 a. <30

850 b. 30-39

851 c. 40-49

852 d. 50-59

853 e. >60

854 2. Gender * Mark only one oval.

855 a. Female

856 b. Male

857 c. Prefer not to say

858 d. Other:

859 3. Number of practicing years * Mark only one oval.

860 a. <5

861 b. 5-10

862 c. 11-20

863 d. 21-30

864 e. >30

865 4. Where did you study medicine? * Mark only one oval.

866 a. Singapore

867 b. Overseas

868 5. What is your specialty?

869 6. I learnt about pharmacogenomics during my medical school * Mark only one oval.

870 a. Yes

871 b. No

872 c. I am not sure

873

874 **Perceptions**

875 7. Are you currently integrating PGx into your clinical practice? * Mark only one oval.

876 a. Yes

877 b. No

878 8. Please rate the following: * Mark only one oval per row.

| | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
|--|-------------------|----------|---------|-------|----------------|
| I am keen in adopting PGx into my clinical practice. | | | | | |
| My patients experience ADRs from their prescribed medications. | | | | | |
| I believe that a patient's genetic profile may influence his/her response to drug therapy. | | | | | |
| In general, the benefits of pharmacogenomics testing outweigh the risks. | | | | | |

879

880 9. PGx is useful for the following: * Mark only one oval per row.

| | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
|--|-------------------|----------|---------|-------|----------------|
| (a) Choosing the best treatment option | | | | | |
| (b) Optimizing drug dosing regimen | | | | | |
| (c) Minimizing ADRs | | | | | |
| (d) Improving treatment efficacy | | | | | |
| (e) Reducing treatment costs | | | | | |

881

882 10. Some of the obstacles involved in implementing PGx into my clinical practice are: *

883 Mark only one oval per row.

| | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
|---------------------------------------|-------------------|----------|---------|-------|----------------|
| (a) Cost | | | | | |
| (b) Turn around time | | | | | |
| (c) Lack of clear guidelines/evidence | | | | | |
| (d) Confuse/worry patients | | | | | |
| (e) PGx is not accurate | | | | | |
| (f) PGx is not applicable to me | | | | | |

884

885 **Ability**

886 11.If I were to adopt PGx into my clinical practice, I know how to do the following: * Mark

887 only one oval per row.

| | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
|--|-------------------|----------|---------|-------|----------------|
| (a) Identifying clinical situations/patients in which PGx is indicated | | | | | |
| (b) Interpret PGx test results | | | | | |
| (c) Make treatment recommendations based on PGx results | | | | | |
| (d) Identify good PGx resources for clinical use | | | | | |
| (e) Explain the rationale of PGx testing to my patients | | | | | |
| (f) Discuss the risks and benefits of PGx testing | | | | | |

888

889 **Knowledge**

890 12. What may be the consequence of a pharmacogenomics polymorphism? Mark only one

891 oval.

892 a. An individual cannot metabolize any drugs

893 b. An individual has a higher risk for toxicity when using prescription drugs

- 894 c. A single drug dose is appropriate for a given indication
 895 d. Individualized dose adjustments should be made according to body surface area
 896
 897 13. What does a poor metabolizer phenotype indicate? Mark only one oval.
 898 a. Lower drug safety because of poor metabolism
 899 b. Good drug efficacy because of poor metabolism
 900 c. Decreased enzyme activity
 901 d. Increased enzyme activity
 902
 903 14. Which of the following is not correct about pre-emptive and reactive genotyping? Mark
 904 only one oval.
 905 a. Reactive genotyping is ordered as a drug therapy is being initiated or contemplated.
 906 b. Pre-emptive genotyping allows pharmacogenomics information to be available to
 907 guide prescribing.
 908 c. Reactive genotyping has been shown to be more cost-effective than pre-emptive
 909 genotyping.
 910 d. Pre-emptive genotyping usually tests for a panel of genes, whereas reactive
 911 genotyping usually tests for one to two genes.
 912

913 **Evaluation**

914 15. Please rate the following: * Mark only one oval per row.

| | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
|---|-------------------|----------|---------|-------|----------------|
| The topics covered were relevant to me. | | | | | |
| The content was organized and easy to follow. | | | | | |
| The patient case aided my understanding of the clinical applications of pharmacogenomics. | | | | | |
| The training expanded my knowledge on pharmacogenomics. | | | | | |

915

916 **Appendix 5: TM2 Course content**

917 Online course can be found here: [https://learning.nalagenetics.com/courses/course-](https://learning.nalagenetics.com/courses/course-v1:nalagenetics+PGX101+2020_Q1)
 918 [v1:nalagenetics+PGX101+2020_Q1](https://learning.nalagenetics.com/courses/course-v1:nalagenetics+PGX101+2020_Q1)

919 **Introduction**

920 Slides 1-3: Introduction of training, speaker and learning objectives

921 Slide 4: Current healthcare landscape

922 Slides 5-6: Introducing Nalagenetics

923 Slide 7: Content Outline

924 **Why do Pharmacogenomics Testing?**

925 Slide 8: Title slide

926 Slides 9-11: Strategies to reduce ADRs

927 Slide 10: Benefits of PGx testing

928 Slides 13-17: Reactive vs pre-emptive genotyping

929 Slides 18-22: Benefits of pre-emptive genotyping

930 Slides 23-26: Patient case scenario

931 **What Fundamentals of Pharmacogenomics I**

932 Slides 27-28: Title slide; Introduction of speaker

933 Slides 29-31: PGx background

934 Slides 32-38: PGx terms and definitions

935 Slides 39-41: Patient case scenario

936 **Where and How Fundamentals of Pharmacogenomics I: PGx**
937 **resources**

938 Slide 42: Title slide

939 Slide 43: Overview

940 Slides 44-45: PharmGKB

941 Slides 46-48: CPIC

942 Slides 49-51: DPWG

943 Slide 52: Regulations

944 Slide 53: Scientific Evidence

945 Slides 54-57: Patient case scenario

946 **Who, When and How Important Pharmacogenes and How to Interpret**
947 **Them**

948 Slide 58: Title slide

949 Slide 59: Overview

950 Slides 60-63: TCAs: amitriptyline and nortriptyline

951 Slides 64-67: Allopurinol and Steven Johnson Syndrome

952 Slides 68-73: Codeine

953 Slides 74-78: Clopidogrel

954 **Where and How How do I implement PGx into my Routine Clinical**
955 **Practice?**

956 Slide 79: Title slide

957 Slides 80-83: Patient case scenario: conclusion

958 Slide 84: Nalagenetics workflow

959 Slides 85-90: Nalagenetics user interface

960 Slides 91-92: Conclusion